未知机构：siRNA药物行业深度黎明已至国产争先siRNA药物机制-20260228

Summary of siRNA Drug Industry Conference Call Industry Overview - The siRNA drug industry is gaining traction as a prominent direction in new drug development due to its ability to precisely silence pathogenic proteins, offering high degradation efficiency and prolonged action time compared to traditional small molecules and biologics [1][1] - The core technology in siRNA drugs is delivery, with a focus on extrahepatic delivery as the current breakthrough area. Various delivery methods include LNP, antibodies, peptides, and VLP, each with its advantages and disadvantages, with AOC showing slightly faster development [1][1] Key Insights - Major international players in the siRNA industry, such as Alnylam, have reached a harvest period with their GalNAc liver delivery system, which is recognized for its high delivery efficiency, strong specificity, and lasting effects. Other companies like Arrowhead and Dicerna are advancing in clinical stages or commercialization targeting cardiovascular common targets like PCSK9, AGT, Lp(a), and ApoC3 [1][1] - Research on extrahepatic organs such as muscles, the nervous system, and eyes is still in early development stages. Alnylam's C16 delivery platform has shown potential in the CNS field, while Arrowhead's TRiM platform has shown promise in adipose tissue, indicating that the discovery of new targets and extrahepatic delivery platforms will be core competitive points in the future [1][1] Domestic Market Dynamics - The domestic siRNA drug development landscape is characterized by a diverse array of startups, with Big Pharma also entering the market. Domestic companies have become significant players in the global siRNA arena, especially as many chronic disease drugs approach the end of their sales lifecycle, necessitating new technological iterations [2][2] - There is a strong business development willingness among multinational corporations (MNCs) in the liver delivery sector, with collaborations established between companies such as 舶望 and Novartis, 圣因 and Roche, 瑞博 and Madrigal, and 前沿 and GSK [2][2] - Domestic enterprises are actively pursuing dual-target and extrahepatic delivery strategies, gradually narrowing the gap with overseas competitors and potentially leading the industry development direction in the future [2][2] Investment Recommendations - Recommended stocks to watch include: - A-shares: 恒瑞医药, 必贝特, 前沿生物, 悦康药业, 阳光诺和, 福元医药 - Hong Kong stocks: 瑞博生物, 石药集团, 中国生物制药, 靖因药业 (already filed for listing) [3][3] - Risk factors to consider include: 1. Clinical progress of innovative drugs not meeting expectations 2. Clinical data of innovative drugs not meeting expectations 3. Sales performance of innovative drugs post-launch not meeting expectations 4. Geopolitical risks [3][3]